Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:348728.
doi: 10.1155/2014/348728. Epub 2014 Mar 18.

EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro

Affiliations

EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro

Hui Xia et al. Biomed Res Int. 2014.

Abstract

Nonsmall-cell lung cancer has a high mortality rate and poor prognosis. In the present study, we silenced EZH2 and explored the consequent cell cycle changes. The expression of cell-cycle-related proteins, including p53, p21, Cdc2, and cyclin B1, was detected with western blotting, and the cell cycle distribution was determined with flow cytometry. Inhibition of EZH2 expression changed the cell cycle distribution, in particular inducing G2/M arrest. Expression of Cdc2 and cyclin B1 was significantly decreased in A549 and HTB-56 cells after EZH2-siRNA treatment. In addition, p53 expression was increased by 21% and 18%, and p21 expression was increased by 31% and 23%, in A549 and HTB-56 cells, respectively, in the presence of EZH2-siRNA. This study clearly demonstrates that modulation of EZH2 expression with siRNA affects the cell cycle and the expression levels of p53 and p21, thereby changing cyclin B1 and Cdc2 expression and inducing G2/M arrest. These results may explain the observed antitumor activity of EZH2 silencing. Such explorations of the molecular mechanism of EZH2 will help us develop novel approaches to the diagnosis, treatment, and prevention of nonsmall-cell lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Influence of EZH2-siRNA on the cell cycle. (a) EZH2 protein expression was analyzed with western blotting after transfection with EZH2-siRNA for 48 or 72 h. (b) The transfection efficiency of EZH2-siRNA was observed after 48 or 72 h. (c) The changes in the cell cycle were observed with FACS analysis after transfection with EZH2-siRNA for 72 h. (d) The effect of EZH2-siRNA after synchronizing the cell cycles at G2/M phase using nocodazole. (e) After treatment with EZH2-siRNA, the expression of cell-cycle-related proteins, including Cdc2 and cyclin B1, was detected using western blotting. Each experiment was performed in triplicate.
Figure 2
Figure 2
Effect of EZH2-siRNA on p53 and p21 protein expression. p53 expression (a) and p21 expression (b) were strongly increased in both A549 and HTB-56 cells after transfection with EZH2-siRNA. (c) Relative expression of p53 mRNA was detected in the presence of GSK 126 or EZH2-siRNA. Each experiment was performed in triplicate.
Figure 3
Figure 3
Effect of EZH2-siRNA on cell cycle progression via the p53 and p21 pathway. (a) The effects of p53-siRNA on the expression of downstream molecular were observed by western blotting. (b) p53 and p21 expression was detected after pifithrin-α application. (c) and (d) Cdc2 and cyclin B1 expression were detected with western blotting after incubation with a p53 inhibitor (pifithrin-α) (c) or p21 inhibitor (adaphostin) (d) in the presence of EZH2-siRNA. (e) The changes in cell cycle progression were observed with FACS analysis after incubation with the p53 or p21 inhibitor in the presence of EZH2-siRNA. Each experiment was performed in triplicate.

References

    1. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2010;28(34):5116–5123. - PubMed
    1. Fuld AD, Dragnev KH, Rigas JR. Pemetrexed in advanced non-small-cell lung cancer. Expert Opinion on Pharmacotherapy. 2010;11(8):1387–1402. - PubMed
    1. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 2007;446(7137):815–819. - PubMed
    1. Suvà ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Research. 2009;69(24):9211–9218. - PubMed
    1. Ronellenfitsch MW, Steinbach JP, Wick W. Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. Targeted Oncology. 2010;5(3):183–191. - PubMed